Semin Thromb Hemost 2013; 39(06): 585-595
DOI: 10.1055/s-0033-1349222
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Congenital Fibrinogen Disorders: An Update

Philippe de Moerloose
1   Division of Angiology and Haemostasis, University Hospital, Geneva, Switzerland
Alessandro Casini
2   Division of Haematology, University Hospital, Geneva, Switzerland
Marguerite Neerman-Arbez
3   Department of Genetic Medicine and Development, University Medical School, Geneva, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2013 (online)


Hereditary fibrinogen abnormalities comprise two classes of plasma fibrinogen defects: Type I, afibrinogenemia or hypofibrinogenemia, which has absent or low plasma fibrinogen antigen levels (quantitative fibrinogen deficiencies), and Type II, dysfibrinogenemia or hypodysfibrinogenemia, which shows normal or reduced antigen levels associated with disproportionately low functional activity (qualitative fibrinogen deficiencies). In afibrinogenemia and hypofibrinogenemia, most mutations of the FGA, FGB, or FGG fibrinogen encoding genes are null mutations. In some cases, missense or late truncating nonsense mutations allow synthesis of the corresponding fibrinogen chain but intracellular fibrinogen assembly and/or secretion are impaired. Afibrinogenemia is associated with mild-to-severe bleeding, whereas hypofibrinogenemia is most often asymptomatic. Thromboembolism may occur either spontaneously or in association with fibrinogen substitution therapy. Women with afibrinogenemia suffer from recurrent pregnancy loss but this can also occur in women with hypofibrinogenemia. Dysfibrinogenemia, caused mainly by missense mutations, is commonly associated with bleeding, thrombophilia, or both; however, most individuals are asymptomatic. Hypodysfibrinogenemia is a subcategory of this disorder. Even in specialized laboratories, the precise diagnosis of some fibrinogen disorders may be difficult. Determination of the molecular defects is important because it gives the possibility to confirm the diagnosis, to elaborate a diagnostic strategy, to distinguish in some cases that the patient is at risk of thrombosis rather than bleeding, and to enable prenatal diagnosis. However, genotype–phenotype correlations are not easy to establish. Replacement therapy is effective in treating bleeding episodes, but because the pharmacokinetics of fibrinogen after replacement therapy is highly variable among patients, it is important to adjust the treatment individually.

  • References

  • 1 Blombäck M, Blombäck B, Mammen EF, Prasad AS. Fibrinogen Detroit—a molecular defect in the N-terminal disulphide knot of human fibrinogen?. Nature 1968; 218 (5137) 134-137
  • 2 Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen [correction of fibrogen] alpha-chain gene (FGA) causes congenital afibrogenemia. J Clin Invest 1999; 103 (2) 215-218
  • 3 de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009; 35 (4) 356-366
  • 4 Neerman-Arbez M, de Moerloose P. Hereditary fibrinogen abnormalities. In: Kaushansky K, Lichtman M, Beutler E, , et al, eds. Williams Hematology. 8th ed. New York, NY: McGraw-Hil; 2010: 1-33
  • 5 Galanakis D. Afibrinogenemias and dysfibrinogenemias. In: Marder V, White GC, Aird WC, , eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012: 693-708
  • 6 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3 (8) 1894-1904
  • 7 Tennent GA, Brennan SO, Stangou AJ, O'Grady J, Hawkins PN, Pepys MB. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109 (5) 1971-1974
  • 8 Medved L, Weisel JW. Fibrinogen and Factor XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 7 (2) 355-359
  • 9 Kant JA, Fornace Jr AJ, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A 1985; 82 (8) 2344-2348
  • 10 de Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 2005; 12 (5) 377-383
  • 11 Huang S, Mulvihill ER, Farrell DH, Chung DW, Davie EW. Biosynthesis of human fibrinogen. Subunit interactions and potential intermediates in the assembly. J Biol Chem 1993; 268 (12) 8919-8926
  • 12 Henschen-Edman AH. On the identification of beneficial and detrimental molecular forms of fibrinogen. Haemostasis 1999; 29 (2-3) 179-186
  • 13 Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol 1972; 22 (6) 681-700
  • 14 Handagama P, Scarborough RM, Shuman MA, Bainton DF. Endocytosis of fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa). Blood 1993; 82 (1) 135-138
  • 15 Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 11-30
  • 16 Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-299
  • 17 Fenton II JW, Olson TA, Zabinski MP, Wilner GD. Anion-binding exosite of human alpha-thrombin and fibrin(ogen) recognition. Biochemistry 1988; 27 (18) 7106-7112
  • 18 Mosesson MW. Update on antithrombin I (fibrin). Thromb Haemost 2007; 98 (1) 105-108
  • 19 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005; 106 (13) 4176-4183
  • 20 Rabe F, Salomon E. Über Faserstoffmangel im Blute bei einem Falle von Hämophilie. Dtsch Arch Klin Med 1920; 132: 240-244
  • 21 World Federation of Hemophilia. Report on the Annual Global Survey 2010. Montreal, Quebec, Canada: World Federation of Hemophilia. 2010 1–45. Available at: . Accessed June 27, 2013.
  • 22 Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107 (1) 204-206
  • 23 Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999; 82 (4) 1207-1214
  • 24 Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104 (5) 1243-1252
  • 25 Viswabandya A, Baidya S, Nair SC , et al. Correlating clinical manifestations with factor levels in rare bleeding disorders: a report from Southern India. Haemophilia 2012; 18 (3) e195-e200
  • 26 Santacroce R, Cappucci F, Pisanelli D , et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis 2006; 17 (4) 235-240
  • 27 Acharya SS, Coughlin A, Dimichele DM. North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2 (2) 248-256
  • 28 Takezawa Y, Terasawa F, Matsuda K , et al. Molecular analysis of afibrinogenemic mutations caused by a homozygous FGA1238 bp deletion, and a compound heterozygous FGA1238 bp deletion and novel FGA c.54+3A>C substitution. Int J Hematol 2012; 96 (1) 39-46
  • 29 Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4 (7) 1634-1637
  • 30 Akcakus M, Patiroglu T, Keskin M, Koklu E, Gozukucuk A. Nonketotic hyperosmolar coma associated with splenic rupture in congenital afibrinogenemia. J Pediatr Hematol Oncol 2004; 26 (10) 668-671
  • 31 Peyvandi F, Kaufman RJ, Seligsohn U , et al. Rare bleeding disorders. Haemophilia 2006; 12 (Suppl. 03) 137-142
  • 32 Aubrey-Bassler FK, Sowers N. 613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review. BMC Emerg Med 2012; 12 (1) 11
  • 33 Rodriguez-Merchan EC. Surgical wound healing in bleeding disorders. Haemophilia 2012; 18 (4) 487-490
  • 34 James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia 2005; 11 (4) 295-307
  • 35 Peyvandi F, Bidlingmaier C, Garagiola I. Management of pregnancy and delivery in women with inherited bleeding disorders. Semin Fetal Neonatal Med 2011; 16 (6) 311-317
  • 36 Cetinkaya SE, Pabuccu EG, Ozmen B, Dokmeci F. Recurrent massive hemoperitoneum due to ovulation as a clinical sign in congenital afibrinogenemia. Acta Obstet Gynecol Scand 2011; 90 (2) 192-194
  • 37 Levrat E, Aboukhamis I, de Moerloose P , et al. A novel frameshift mutation in FGA (c.1846 del A) leading to congenital afibrinogenemia in a consanguineous Syrian family. Blood Coagul Fibrinolysis 2011; 22 (2) 148-150
  • 38 Suh TT, Holmbäck K, Jensen NJ , et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9 (16) 2020-2033
  • 39 Iwaki T, Sandoval-Cooper MJ, Paiva M, Kobayashi T, Ploplis VA, Castellino FJ. Fibrinogen stabilizes placental-maternal attachment during embryonic development in the mouse. Am J Pathol 2002; 160 (3) 1021-1034
  • 40 de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost 2010; 36 (1) 7-17
  • 41 Grandone E, Tiscia G, Cappucci F , et al. Clinical histories and molecular characterization of two afibrinogenemic patients: insights into clinical management. Haemophilia 2012; 18 (1) e16-e18
  • 42 Chevalier Y, Dargaud Y, Argaud L, Ninet J, Jouanneau E, Négrier C. Successive bleeding and thrombotic complications in a patient with afibrinogenemia: a case report. Thromb Res 2011; 128 (3) 296-298
  • 43 Ruiz-Sáez A. Thrombosis in rare bleeding disorders. Hematology 2012; 17 (Suppl. 01) S156-S158
  • 44 De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986; 77 (4) 1272-1277
  • 45 Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Investig 1994; 72 (5) 396-398
  • 46 de Bosch NB, Mosesson MW, Ruiz-Sáez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost 2002; 88 (2) 253-258
  • 47 Mosesson MW, Antithrombin I. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89 (1) 9-12
  • 48 Ni H, Denis CV, Subbarao S , et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106 (3) 385-392
  • 49 Remijn JA, Wu YP, Ijsseldijk MJ, Zwaginga JJ, Sixma JJ, de Groot PG. Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions. Thromb Haemost 2001; 85 (4) 736-742
  • 50 Risak E. Die fibrinogenie. Z Klin Med 1935; 128: 605
  • 51 Peyvandi F, Palla R, Menegatti M , et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (4) 615-621
  • 52 Kobayashi T, Kanayama N, Tokunaga N, Asahina T, Terao T. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 2000; 109 (2) 364-366
  • 53 Hill MB, Brennan SO, Dear A, Strong J, Nejim T, Dolan G. Fibrinogen Nottingham II: a novel Bbeta Arg264gly substitution causing hypofibrinogenaemia. Thromb Haemost 2006; 96 (3) 378-380
  • 54 Dib N, Quelin F, Ternisien C , et al. Fibrinogen angers with a new deletion (gamma GVYYQ 346-350) causes hypofibrinogenemia with hepatic storage. J Thromb Haemost 2007; 5 (10) 1999-2005
  • 55 Brennan SO, Davis RL, Conard K, Savo A, Furuya KN. Novel fibrinogen mutation γ314Thr→Pro (fibrinogen AI duPont) associated with hepatic fibrinogen storage disease and hypofibrinogenaemia. Liver Int 2010; 30 (10) 1541-1547
  • 56 Brennan SO, Maghzal G, Shneider BL, Gordon R, Magid MS, George PM. Novel fibrinogen gamma375 Arg—>Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 2002; 36 (3) 652-658
  • 57 Brennan SO, Wyatt J, Medicina D, Callea F, George PM. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly—>Arg mutation. Am J Pathol 2000; 157 (1) 189-196
  • 58 Imperato C, Dettori AG. [Congenital hypofibrinogenemia with fibrinoasthenia]. Helv Paediatr Acta 1958; 13 (4) 380-399
  • 59 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73 (1) 151-161
  • 60 Morris TA, Marsh JJ, Chiles PG , et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009; 114 (9) 1929-1936
  • 61 Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002; 126 (11) 1387-1390
  • 62 Gillmore JD, Lachmann HJ, Rowczenio D , et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 2009; 20 (2) 444-451
  • 63 Tavares I, Lobato L, Moreira L , et al. Long-term follow-up of patients with hereditary fibrinogen A alpha-chain amyloidosis. Amyloid 2011; 18 (Suppl. 01) 221-222
  • 64 Pinney JH, Lachmann HJ, Sattianayagam PT , et al. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant 2013; 13 (2) 433-441
  • 65 Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis 2010; 21 (1) 35-40
  • 66 Dupuy E, Soria C, Molho P , et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102 (3) 211-219
  • 67 Colvin RB, Mosesson MW, Dvorak HF. Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest 1979; 63 (6) 1302-1306
  • 68 Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001; 114 (2) 249-257
  • 69 Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res 2010; 126 (6) e428-e433
  • 70 Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007; 5 (Suppl. 01) 125-131
  • 71 Tirefort Y, Alson OR, de Moerloose P, Neerman-Arbez M. Mutation of the translation initiation codon in FGA causes congenital afibrinogenemia. Blood Coagul Fibrinolysis 2012; 23 (6) 556-558
  • 72 Galanakis DK, Neerman-Arbez M, Scheiner T , et al. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release. Blood Coagul Fibrinolysis 2007; 18 (8) 731-737
  • 73 Abdel Wahab M, de Moerloose P, Fish RJ, Neerman-Arbez M. Identification and functional characterization of a novel nonsense mutation in FGA accounting for congenital afibrinogenemia in six Egyptian patients. Blood Coagul Fibrinolysis 2010; 21 (2) 164-167
  • 74 Robert-Ebadi H, de Moerloose P, El Khorassani M, El Khattab M, Neerman-Arbez M. A novel frameshift mutation in FGA accounting for congenital afibrinogenemia predicted to encode an aberrant peptide terminating 158 amino acids downstream. Blood Coagul Fibrinolysis 2009; 20 (5) 385-387
  • 75 Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90
  • 76 Vorjohann S, Fish RJ, Biron-Andréani C , et al. Hypodysfibrinogenaemia due to production of mutant fibrinogen alpha-chains lacking fibrinopeptide A and polymerisation knob 'A'. Thromb Haemost 2010; 104 (5) 990-997
  • 77 Lefebvre P, Velasco PT, Dear A , et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood 2004; 103 (7) 2571-2576
  • 78 Jayo A, Arnold E, González-Manchón C, Green D, Lord ST. Hypodysfibrinogenemia causing mild bleeding and thrombotic complications in a compound heterozygote of AalphaIVS4+1G>T mutation and Aalpha4841delC truncation (Aalpha(Perth)). Thromb Haemost 2009; 101 (4) 770-772
  • 79 Meyer M, Dietzel H, Kaetzel R, Schmidt D, Liebscher K, Brennan SO. Fibrinogen Leipzig II (gamma351Gly—>Ser and gamma82Ala—>Gly): hypodysfibrinogenaemia due to two independent amino acid substitutions within the same polypeptide chain. Thromb Haemost 2007; 98 (4) 903-905
  • 80 Ridgway HJ, Brennan SO, Faed JM, George PM. Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98 (3) 632-639
  • 81 Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA—>stop TAA). Blood 1992; 80 (8) 1972-1979
  • 82 Ding Q, Ouyang Q, Xi X, Wang X, Shen Y, Wang H. Maternal chromosome 4 heterodisomy/isodisomy and Bβ chain Trp323X mutation resulting in severe hypodysfibrinogenaemia. Thromb Haemost 2012; 108 (4) 654-661
  • 83 Mc Donagh J. Dysfibrinogenemia and other disorders of fibrinogen structure or function. In: Colman RW, Hirsh J, Marder V, Clowes A, George J, , eds. Hemostasis and Thrombosis Basic Principles and Clinical Practice. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 855-892
  • 84 Siebenlist KR, Mosesson MW, Meh DA, DiOrio JP, Albrecht RM, Olson JD. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis 2000; 11 (3) 293-304
  • 85 Travlou A, Gialeraki A, Merkouri E, Politou M, Sfyridaki A, Neerman-Arbez M. Coexisting dysfibrinogenemia (gamma Arg275His) and FV Leiden associated with thrombosis (Fibrinogen Crete). Thromb Res 2010; 126 (2) e162-e164
  • 86 Barrowcliffe TW, Cattaneo M, Podda GM , et al. New approaches for measuring coagulation. Haemophilia 2006; 12 (Suppl. 03) 76-81
  • 87 Kalina U, Stöhr HA, Bickhard H , et al. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis 2008; 19 (8) 777-783
  • 88 Neerman-Arbez M, Vu D, Abu-Libdeh B, Bouchardy I, Morris MA. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. Blood 2003; 101 (9) 3492-3494
  • 89 de Moerloose P, Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther 2008; 8 (7) 979-992
  • 90 Bolton-Maggs PH, Perry DJ, Chalmers EA , et al. The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10 (5) 593-628
  • 91 De Vries A, Rosenberg T, Kochwa S, Boss JH. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med 1961; 30: 486-494
  • 92 Ra'anani P, Levi Y, Varon D, Gitel S, Martinowitz U. [Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen]. Harefuah 1991; 121 (9) 291-293
  • 93 Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9 (9) 1687-1704
  • 94 Schuepbach RA, Meili EO, Schneider E, Peter U, Bachli EB. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia. Thromb Haemost 2004; 91 (5) 1044-1046
  • 95 Grech H, Majumdar G, Lawrie AS, Savidge GF. Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature. Br J Haematol 1991; 78 (4) 571-572
  • 96 Huq FY, Kadir RA. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia 2011; 17 (Suppl. 01) 20-30